Clinical trial
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
NCT00267527 · ConjuChem, Industry · Terminated
Key facts
| NCT number | NCT00267527 |
|---|---|
| Title | A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity |
| Lead sponsor | ConjuChem, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obesity, HIV Infections |
| Intervention type | Drug |
| Interventions | CJC 1295 |
| Enrollment | 120 |
| Start date | Dec 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Dec 21, 2005 |
| Last update posted | Oct 16, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: